Pharmaceutical News

RSS

WHO calls for greater vigilance on correct use of antibiotics against gonorrhoea

Millions of people with gonorrhoea may be at risk of running out of treatment options unless urgent action is taken, according to WHO. Already several countries, including Australia, France, Japan, Norway, Sweden and the United Kingdom are reporting cases of resistance to cephalosporin antibiotics - the last treatment option against gonorrhoea. Every year an estimated 106 million people are infected with gonorrhea, which is transmitted sexually.

7 Jun 2012

New nanomedicine cancer treatments promise to reduce severity of side effects

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the current edition of Chemical & Engineering News.

7 Jun 2012

Cellana launches ReNew line of products at GOED conference

Cellana, Inc. announced the launch of its ReNew brand and ReNew Omega-3 line of algae-based products at the GOED (Global Organization for EPA and DHA) conference being held this week in Boston, Massachusetts.

7 Jun 2012

DODAC to discuss ThromboGenics’ new BLA for ocriplasmin intravitreal injection

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.

7 Jun 2012

CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing

The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research.

7 Jun 2012

Vitamin D deficiency may be an important risk factor for erectile dysfunction

A paper just published hypothesizes that vitamin D deficiency may be an important risk factor for erectile dysfunction (ED).

7 Jun 2012

Boehringer Ingelheim updates U.S. prescribing information for Pradaxa with FDA

Boehringer Ingelheim has today announced that it has updated the US prescribing information for Pradaxa (dabigatran etexilate) in alignment with the US Food and Drug Administration (FDA) to affirm that "Pradaxa 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin."

7 Jun 2012

Arrowhead initiates final IND-enabling steps for ARC-520 to treat HBV

Arrowhead Research Corporation, a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical candidate.

7 Jun 2012

Follow-up study finds seizure freedom in 68% of patients with JME

A 25-year follow-up study reveals that 68% of patients with juvenile myoclonic epilepsy (JME) became seizure-free, with nearly 30% no longer needing antiepileptic drug (AED) treatment. Findings published today in Epilepsia, a journal of the International League Against Epilepsy (ILAE), report that the occurrence of generalized tonic-clonic seizures preceded by bilateral myoclonic seizures, and AED polytherapy significantly predicted poor long-term seizure outcome.

6 Jun 2012

Study determines transgenerational effects of cannabinoid exposure in adolescent female rats

Mothers who use marijuana as teens-long before having children-may put their future children at a higher risk of drug abuse, new research suggests.

6 Jun 2012

Arte, ProJect Pharmaceutics partner to develop Lyo-DCPS

Arte Corporation and ProJect Pharmaceutics have been working closely on the development of a new type of dual chamber prefillable syringe for freeze-dried pharmaceuticals. The two companies have joined together with the objective to provide innovative dual chamber syringes for the global pharmaceutical market.

6 Jun 2012

FDA issues complete response letter to Merck’s ridaforolimus NDA

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for ridaforolimus.

6 Jun 2012

BioLineRx receives two U.S. patent allowances for BL-1021 to treat neuropathic pain

BioLineRx, a biopharmaceutical development company, announced today that two Notices of Allowance have been issued by the United States Patent and Trademark Office (USPTO) for BL-1021, an orally available small molecule for treating neuropathic pain.

6 Jun 2012

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

ThromboGenics NV and co-development partner BioInvent International announce today that they will regain global rights to TB-403 from Roche.

6 Jun 2012

FDA approves Lupin’s SUPRAX capsules

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. has received approval for SUPRAX (Cefixime) Capsules 400 mg from the United States Food and Drugs Administration (FDA).

6 Jun 2012

Family members of children with staph infections often harbor drug-resistant germs

Family members of children with a staph infection often harbor a drug-resistant form of the germ, although they don't show symptoms, a team of researchers from Washington University School of Medicine in St. Louis has found.

5 Jun 2012

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.

5 Jun 2012

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Researchers at Universitat Aut-noma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the --amyloid protein, involved in Alzheimer's disease.

5 Jun 2012

Androgen receptor an additional hormonal target in many breast cancers

Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) receptor is an additional hormonal target in many breast cancers. Block AR+ breast cancer's ability to access androgen and you block the cancer's ability to survive.

5 Jun 2012

Nouveau Life launches new weight loss supplement

Nouveau Life Pharmaceuticals Inc., a leading provider of quality all-natural dietary supplements, announced today the release of its newest supplement product: New Life Naturals: For Your Weight Loss.

5 Jun 2012